L Wang
Mayo Clinic
7 Papers
16 Citations
L Wang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.
Yu Zhao,Liguo Wang,Shancheng Ren,L Wang,Patrick R. Blackburn,Melissa S. McNulty,Xu Gao,Meng Qiao,Robert L. Vessella,Manish Kohli,Jun Zhang,R. Jeffrey Karnes,Donald J. Tindall,Youngsoo Kim,Robert A. Macleod,Stephen C. Ekker,Tiebang Kang,Yinghao Sun,Haojie Huang +18 more
TL;DR: A P-TEFb activation mechanism is uncovered and altered eRNA expression that is related to abnormal AR function and may potentially be a therapeutic target in CRPC is revealed.
125
Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study
PA Fasching,S. Loibl,H Eidtmann,Hans Tesch,Michael Untch,Jörn Hilfrich,Christian Schem,Mahdi Rezai,Bernd Gerber,S. D. Costa,J-U Blohmer,Tanja Fehm,J Huober,Cornelia Liedtke,V Müller,Valentina Nekljudova,Karsten Weber,Brigitte Rack,Matthias Rübner,L Wang,JN Ingle,Richard M. Weinshilboum,G. von Minckwitz,Fergus J. Couch +23 more
TL;DR: TNBC Patients with BRCA mutations showed a higher frequency of pCR than patients without BRC a mutations after treatment with epirubicin, cyclophosphamide and docetaxel (+/ bevacizumab), suggesting that BRCa mutations may influence pCR in response to treatment regimens that do not include platin chemotherapy.
10
Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration
JN Ingle,MC Liu,D L Wickerham,Daniel J. Schaid,Taisei Mushiroda,Michiaki Kubo,Joseph P. Costantino,Matthew P. Goetz,Matthew M. Ames,L Wang,Victor G. Vogel,Soonmyung Paik,Anthony Batzler,DA Flockhart,Norman Wolmark,Yusuke Nakamura,Richard M. Weinshilboum +16 more
TL;DR: A nested matched case-control genome-wide association study revealed SNPs associated with the development of breast cancer in high-risk women treated with tamoxifen or raloxifene, and these SNPs displayed striking differences in estradiol-induced expression of ZNF423, SMAD3, BRCA1, and BRC a2 in vitro, providing direction for future research.
4
Abstract P1-08-10: Integration of next generation sequencing (NGS) and patient derived xenografts (PDX) to identify novel markers of paclitaxel (T) response in the breast cancer genome guided therapy study (BEAUTY)
Matthew P. Goetz,Judy C. Boughey,Krishna R. Kalari,Jeanette E. Eckel-Passow,VJ Suman,Hugues Sicotte,Steven N. Hart,Ann M. Moyer,DW Visscher,Jia Yu,Bowen Gao,Jason P. Sinnwell,Douglas W. Mahoney,Poulami Barman,Peter T. Vedell,Xiaojia Tang,Kevin J. Thompson,Travis J. Dockter,Katie N. Jones,Amy Lynn Conners,Sarah A. McLaughlin,Alvaro Moreno-Aspitia,Donald W. Northfelt,Richard Gray,Eric D. Wieben,Gianrico Farrugia,Cloann G. Schultz,JN Ingle,L Wang,RW Weinshilboum +29 more
TL;DR: This is the first prospective study to demonstrate the feasibility of using PTB to obtain both NGS data and PDX in the neoadjuvant setting and validate genes/pathways associated with treatment response in subsequent BEAUTY pts.
2
Abstract 5358: BRCA1 is a negative modulator of the PRC2 complex.
TL;DR: It is shown that the tumor suppressor protein BRCA1 interacts with EZH2 and other components of PRC2 in mouse embryonic stem (ES) and human breast cancer cells and that loss of BRC a1 inhibits ES cell differentiation and enhances cancer aggressive phenotypes via augmented PRC 2 function.
1